Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Blueprint Medicines Fell as Much as 15.1% Today

By Maxx Chatsko – Apr 16, 2018 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma reported encouraging data from a phase 1 trial. Er, wait, what?

What happened

Shares of clinical-stage biopharma Blueprint Medicines (BPMC 1.95%) dropped over 15% today after the company reported data from a phase 1 trial for BLU-667 in patients with three types of cancers in which the RET gene is overexpressed. The gene-targeting approach elicited tumor shrinkage in 84% of patients taking the drug candidate, although only 45% of responses across the study were considered significant. 

Wall Street seems to be taking issue with how the drug candidate appeared to fare in each of the three types of cancers studied. The preliminary data show BLU-667 delivered the lowest response rate in the most common RET-altered cancer, but analysts could be overreacting.

As of 12:10 p.m. EDT, the stock had settled to a 13.3% loss. The stock is up 355% in the last three years.

A graph on a chalkboard showing a steep decline after rising sharply.

Image source: Getty Images.

So what

Blueprint Medicines is investigating whether BLU-667 can become a treatment for cancers expressing the RET gene. While many different tumor types have been shown to utilize the gene, the current phase 1 trial started by looking at three cancers: non-smal-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer (PTC).

There were 14 evaluable patients with NSCLC, 25 with MTC, and one with PTC. The overall response rates were 50% for the evaluable patients with NSCLC, 40% for the evaluable patients with MTC, and 100% for PTC (there was only one evaluable patient).

Wall Street seems to be concerned with the overall response rates for MTC. That's because RET-altered cancers represent nearly 60% of all MTC cases, but only 1% to 2% of NSCLC cases. In other words, analysts are already looking ahead to the potential patient populations that could be treated with an RET-gene-targeting therapy.

Now what

Of course, the data were reported from an early-stage trial, so it seems a little silly to draw firm conclusions about the 40% overall response rate. The number will change -- for better or for worse -- as the trial expands to include more patients. Some analysts think Blueprint Medicines will achieve even better response rates in the future, because the phase 1 trial was aimed at evaluating the safety of BLU-667, not optimizing its dose. But there was a dose-dependent response, so putting more patients on higher doses could result in a higher overall response rate.

For now, investors should be encouraged by the results from the early-stage trial while not forgetting that there's a long way to go. That said, the emergence of gene-targeted therapeutic drug candidates appears to be a positive trend for the industry, patients, and investors.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Blueprint Medicines Stock Quote
Blueprint Medicines
$67.63 (1.95%) $1.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.